Deliver timeline: Commercial Production by December end 2029

Location: Concord, North Carolina

Network: Parenteral

The Concord facility produces injectable medicines and auto-injector devices to support Lilly’s growing diabetes and obesity portfolio. Spanning 1.3 million square feet across 10 automated, robotics-enabled buildings, the site began operations in 2024. It employs more than 750 people and plays a key role in meeting global demand for Mounjaro and Zepbound.